Abstract Actinomycetes are one of the most effi cient groups of secondary metabolite producers and are very important from an industrial point of view. Among its various genera, Streptomyces, Saccharopolyspora, Amycolatopsis, Micromonospora and Actinoplanes are the major producers of commercially important biomolecules. Several species have been isolated and screened from the soil in the past decades. Consequently the chance of isolating a novel actinomycete strain from a terrestrial habitat, which would produce new biologically active metabolites, has reduced. The most relevant reason for discovering novel secondary metabolites is to circumvent the problem of resistant pathogens, which are no longer susceptible to the currently used drugs. Existence of actinomycetes has been reported in the hitherto untapped marine ecosystem. Marine actinomycetes are effi cient producers of new secondary metabolites that show a range of biological activities including antibacterial, antifungal, anticancer, insecticidal and enzyme inhibition. Bioactive compounds from marine actinomycetes possess distinct chemical structures that may form the basis for synthesis of new drugs that could be used to combat resistant pathogens.
Introduction
Microbial natural products are an important source of both existing and new drugs. Among the producers of commercially important metabolites, bacteria have proven to be a prolifi c source with a surprisingly small group of taxa accounting for the vast majority of compounds discovered till date [1] . Among these, Actinomycetes are the most economically and biotechnologically priceless prokaryotes. Representative genera of actinomycetes include Streptomyces, Actinomyces, Arthrobacter, Corynebacterium, Frankia, Micrococcus, Micromonospora and several others. Secondary metabolites produced by actinomycetes possess a wide range of biological activities [1] [2] [3] [4] . The genus Streptomyces alone produces a large number of bioactive molecules . It has an enormous biosynthetic potential that remains unchallenged without a potential competitor among other microbial groups. A large number of Streptomyces spp. have been isolated and screened from soil in the past several decades [129, 130] . Consequently the chances of isolating a novel Streptomyces strain from terrestrial habitats have diminished. Above 500 species of Streptomyces account for 70-80% of relevant secondary metabolites as shown in Table 1 [ , with small contributions from other genera, such as Saccharopolyspora, Amycolatopsis, Micromonospora and Actinoplanes. An important reason for discovering novel secondary metabolites is to circumvent the problem of resistant pathogens, which are no longer susceptible to the currently used drugs [131, 132] . The number of deaths due to these clever pathogenic organisms is on the rise. Secondary metabolites from marine [133, 134] . Existence of cousins of terrestrial actinomycetes has been reported in the relatively untapped marine ecosystem. The immense diversity of this habitat along with it's underexploitation is the fundamental reason for attracting researchers towards it for discovering novel metabolite producers. Actinomycetes comprise about 10% of the bacteria colonizing marine aggregates and can be isolated from marine sediments [135] . Many actinomycete isolates from deep oceans contain non-ribosomal polyketide synthetase (NRPS) and polyketide synthetase (PKS) pathways, the hallmarks of secondary metabolite production [136] . There is an occurrence of distinct rare genera in the marine ecosystem as evidenced by the taxonomic description of the fi rst marine actinomycete Rhodococcus marinonascens [137] . Actinomycetes have also been isolated from free swimming as well as sessile marine vertebrates and invertebrates [135] . Unusual actinomycetes belonging to Micrococceae, Dermatophilaceae and Gordoniaceae, have been isolated from sponges [133] . Tetrodotoxin-producing actinomycete has been isolated from puffer fi sh ovaries [138] , the organism was found to be most closely related to Nocardiopsis dassonvillei.
Researchers are fi nding new genera from marine environments on a regular basis and discovering new metabolite producers never reported earlier. [135] . Inspite of improvements being made in the cultural methods for the isolation of rare marine actinomycetes, many of these organisms still remain unculturable and have to be detected by using molecular techniques [139, 140] . Metagenomic methods are useful for characterizing microbes that cannot be cultivated and can also be used to isolate their genes [141] .
Secondary metabolites from marine actinomycetes
Marine actinomycetes have proven to be effi cient producers of new secondary metabolites as shown in Table 2 , which show a range of biological activities such as antifungal, antitumor, antibacterial, immunosuppressive, insecticidal and enzyme inhibition, to name a few.
Secondary metabolites produced by marine actinomycetes can be classifi ed on the basis of their chemical structure as follows:
Terpenes and terpenoids
The most chemically diverse pool of secondary metabolites in nature is constituted by terpenes [183] . In 1956, novobiocin was isolated as the fi rst antibiotic with a terpenoid side chain from Streptomyces niveus [184] . After this, the list of these compounds isolated from soil actinomycetes has increased as listed in Table 3 [ [185] [186] [187] [188] [189] [190] [191] [192] [193] .
Terpenes are not only produced by the soil actinomycetes but also from the marine habitants as evidenced by the following compounds:
I. Azamerone [142] is a meroterpenoid produced by a new marine bacterium related to the genus Streptomyces. It appears to be the fi rst natural product with a phthalazione ring (Fig. 1) . II. Three new pyrrolosesquiterpenes, glaciapyrroles A, B and C [143] are produced by a Streptomyces strain (NPSOO 8187). These compounds show antibacterial [144] (Fig. 3) namely 10α,15-dihydroxyamorph-4-en-3-one, 10α,11-dihydr -oxyamorph-4-ene and 5α,10α,11-trihydroxyamor phan-3-one are produced by Streptomyces sp. M491. This is the fi rst report of these sesquiterpenes from bacteria. IV. Neomarinone [145] , a novel metabolite possessing a new sesquiterpene and polyketide-derived carbon skeleton and several derivatives of the marinone class of naphthoquinone antibiotics are produced by a taxonomically novel marine actinomycete (strain CNH-099). These bioactive molecules show moderate cytotoxicity towards human cancer cells.
Polyketides
I. Saliniketal A (Fig. 4 ) and saliniketal B [146, 147] , produced by Salinispora arenicola, are inhibitors of ornithine decarboxylase biosynthesis. Inhibition of ornithine decarboxylase production is an important strategy in the control of cancer since high levels of this enzyme lead to uncontrolled proliferation of cells. The Saliniketals are partly related in structure to the rifamycins. II. Abyssomicin C [148] (Fig. 5 ) is a polycyclic polyketide produced by Verrucosispora. It targets p-aminobenzoate (PABA) biosynthesis and therefore inhibits folic acid biosynthesis at an early stage as compared to the well-known synthetic sulpha drugs. The abyssomicins are the fi rst known bacterial secondary metabolites that can inhibit the biosynthesis of PABA. Targeting PABA production is an attractive strategy for arresting microbial growth since PABA directly leads to the production of folic acid, which is a precursor of purine biosynthesis. Humans lack this pathway; therefore the strategy will not be harmful to humans. Abyssomicin C shows antibacterial activity against gram-positive bacteria as well as clinical isolates of multiple resistant and vancomycin-resistant Staphylococcus aureus. Abyssomicin C and its analogues thus have a high potential to be developed as antibacterial agents against drug-resistant pathogens. III. A marine inhabitant known as Streptomyces psommoticus produces antibiotic SBR-22 [149] . It shows antibacterial activity against methicillin-resistant Staphylococcus aureus. IV. Daryamides [150] (Fig. 6 ) are cytotoxic polyketides isolated from culture broth of a Streptomyces strain, CNQ-085. These bioactive compounds show weak to moderate cytotoxicity against the human colon carcinoma cell line HCT-116 and very weak antifungal activities against Candida albicans. V. Actinofuranones A and B [151] (Fig. 7) are isolated from the fermentation broth of a marine bacterium related to Streptomyces genus. Actinofuranones A and B show weak in vitro cytotoxicity against mouse splenocyte T-cells and macrophages.
3. Peptides I. Mechercharmycins [152] are new bioactive compounds obtained from marine-derived Thermoactinomyces sp. YM3-251. The cyclic structure of mechercharmycin A ( Fig. 8) is essential for its strong antitumor activity, since the related compound mechercharmycin B (Fig. 9) does not show such an activity. II. Thiocoraline [153] is a new depsipeptide isolated from Micromonospora. It shows potent cytotoxicity against P-388, A-549 and MEL cell lines, and also a strong antimicrobial activity against gram-positive microorganisms. This compound binds to supercoiled DNA and inhibits RNA synthesis. III. Cyclomarins A-C [154] (Fig. 10) are cyclic peptides produced by a Streptomyces sp. They show antiinfl ammatory and antiviral activities. IV. Piperazimycins [155] (Fig. 11) are cytotoxic hexadepsipeptides isolated from the fermentation broth of a Streptomyces sp. Piperazimycin A exhibits potent in vitro cytotoxicity against multiple tumor cell lines. V. Two cyclic peptides dehydroxynocardamine [156] and desmethylenylnocardamine [156] along with nocardamine have been isolated from a Streptomyces sp. which has been obtained from an unidentifi ed marine sponge. These new compounds exhibit weak inhibition against the enzyme sortase B. VI. Urukthapelstatin A [157] is a novel cyclic peptide produced by the thermoactinomycete bacterium Mechercharimyces asporophorigenes YM11-542. It inhibits the growth of human lung cancer A54 cells and shows cytotoxicity against a range of human cancer cell lines. VII. Salinamides [158] A and B are bicyclic depsipeptides produced by a Streptomyces sp., CNB-091, isolated from jelly fi sh Cassiopeia xamachana. These metabolites are useful as antibiotic and anti-infl ammatory agents.
Caprolactones
Two new caprolactones R-10-methyl-6-undecanolide and (6R,10S)-10-methyl-6-dodeconolide [159] are produced by a marine Streptomyces sp. isolate B6007. These caprolactones show a moderate phytotoxicity and low cytotoxocity against cancer cells.
Butenolides
Streptoverticillium luteoverticillatum produces four butenolides [160] . These butenolides show cytotoxicity against the murine lymphoma P388 and human leukemia K562 cell lines. This is the fi rst report of isolation of butenolides from the marine ecosystem, which possess cytotoxic activity.
6. Polycyclic xanthones IB-00208 [161] is a polycyclic xanthone isolated from the culture of Actinomadura. This compound possesses cytotoxicity against tumor cell lines and bactericidal activity against gram-positive bacteria.
Piericidins
Piericidins C7 and C8 [162] show selective cytotoxicity against rat glia cells transformed with the adenovirus EIA gene and neuro-2a mouse neuroblastoma cells. These compounds are produced by a marine Streptomyces sp.
Quinones
I. Resistomycin [163] (Fig. 12) , an antibiotic related to quinones, is produced by Streptomyces corchorusii AUBN(1)/7. This is an inhibitor of HIV-1 protease. II. Tetracenomycin D [164] (Fig. 13) is an anthraquinone antibiotic also produced by Streptomyces corchorusii AUBN(1)/7. It shows cytotoxicity against cell line HMO2 (gastric adenocarcinoma) and HepG2 (hepatic carcinoma) and possesses weak antibacterial activities against gram-positive and gram-negative bacteria. III. Resistofl avine [165, 166] (Fig. 14) is produced by Streptomyces chibaensis AUBN(1)/7. It shows cytotoxicity against cell line HMO2 (gastric adenocarcinoma) and HepG2 (hepatic carcinoma) and possesses weak antibacterial activities against gram-positive and gram-negative bacteria. IV. Komodoquinone A [167] (Fig. 15) is a neuritogenic anthracycline isolated from the fermentation broth of a marine Streptomyces sp. K53. It induces cell differentiation in the neuroblastoma cell line, Neuro2A and arrests cell cycle at the G1 phase. V. Himalomycins A and B [168] (Fig. 16) viridochromogenes, Staphylococcus aureus and Escherichia coli. VI. Helquinolines [169] (Fig. 17) (Fig. 18) and also some terpenes. II. Some strains of Salinispora arenicola produce a series of macrolides exemplifi ed by Arenicolide [147, 171] ( Fig. 19) . These possess weak antibacterial activities against drug-resistant bacteria. III. Marinomycins [172] (Fig. 20) are polyene-like macrolides. A marine Marinispora produces these compounds, which are potent antitumor antibiotics with moderate activities against selected human tumors and drug-resistant bacterial pathogens. Marinomycin A inhibits the growth of human pathogenic bacteria such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. These polyenes are highly photoreactive and undergo isomerization even at room light because of which their use in clinics as potential drugs has been discontinued. In spite of being polyenes, marinomycins however, do not shows antifungal activities typically associated with other polyene antibiotics.
Alkaloids
Two indolocarbazole alkaloids, K252c [173] (Fig. 21) and Arcyriafl avin A [173] (Fig. 22 ) are produced by a marine actinomycete Z(2)0392. Both of these alkaloids possess moderate cytotoxicity against the K562 cell line and induce apoptosis. This is the fi rst report of the signifi cant apoptosis inducing effect of indolocarbazole alkaloids against K562 cancer cells.
Esters
Bonactin [174] (Fig. 23) is an antimicrobial ester. Bonactin displays antimicrobial activity against gram-positive and gram-negative bacteria as well as against several fungi. Bonactin is produced by Streptomyces sp. BD21-2.
Chinikomycins
Chinikomycins A (Fig. 24) and B [175] are chlorinecontaining aromatic manumycin derivatives. They exhibit antitumor activity against different human cancer cell lines, 
Trioxacarcins
Trioxacarcins [176] (Fig. 25 ) are complex compounds showing high antibacterial activity against gram-positive and gram-negative bacteria, and some of them show high antitumor and antimalarial activities as well. Trioxacarcin A also exhibits antifungal activities. Trioxacarcin A, B and C are obtained from Streptomyces ochraceus and Streptomyces bottropensis. Some of these compounds possess extremely high antiplasmodial activity, which is comparable to that shown by artemisinin, the most active compound against the pathogen of malaria. The producers of trioxacarcins also biosynthesize the related metabolite, gutingimycin.
Methylpyridine
Streptokordin [177] a new cytotoxic compound of the methylpyridine class is isolated from the cultural broth of Streptomyces sp. KORDI-3238. It exhibits signifi cant cytotoxicity against several human cancer cell lines but shows no growth inhibition against various microorganisms, including bacteria and fungi. (Fig. 26 ) is produced by Salinispora tropica which is found in oceanic sediments. Salinosporamide A is a potent proteasome inhibitor used as an anticancer agent that has entered phase I of the human clinical trials for the treatment of multiple myeloma. It inhibits proteasome activity by covalently modifying the active site threonine residues of the 20S proteasome. II. Aureoverticillactam, a novel 22-atom macrocyclic lactam [179] is isolated from Streptomyces aureoverticillaris. It shows cytotoxicity against various tumor cell lines. Salinosporamide A and aureoverticillactam are lactams from marine actinomycetes. These are distinct from β-lactam compounds which contain a four-membered β-lactam ring. The structure of β-lactam second ring allows these compounds to be classifi ed into penicillins, cephalosporins, clavams, carbapenes and monobactans [194] . Most β-lactam compounds inhibit bacterial cell wall synthesis but others behave as β-lactamase inhibitors (e.g. cluvalanic acid) and even as antifungal agents (e.g. some clavams) [194] , however salinosporamide A and aureoverticillactam show cytotoxicity against cancer cells.
Enzyme inhibitors
Some of the enzymes inhibitors reported from marine actinomycetes include:
I. Alpha amylase inhibitor from Streptomyces corchorusii subsp. rhodomarinus. subsp. nov [180] .
II. Pyrostatins A and B are inhibitors of n-acetyl-beta-glucosaminidase, produced by Streptomyces sp. SA-3501 [181] . III. Pyrizinostatin is an inhibitor of pyroglutamyl peptidase, isolated from culture of Streptomyces sp. SA-2289 [182] . 
Conclusion
Secondary metabolites produced from marine actinomycetes have distinct chemical structures, which may form the basis for the synthesis of new drugs. Salinispora alone produces a wide range of metabolites having different biological activities [146, 147, 171, 178] . Enrichment and selective isolation methods can also be used to isolate rare actinomycetes from marine ecological niches having the potential to biosynthesize novel bioactive compounds [140, [195] [196] [197] . A great hurdle however, in the search of these actinomycetes is that more than 90% of the organisms remain uncultivable under laboratory conditions. To explore the genomic diversity of the marine ecosystem and estimate their biosynthetic capability, the techniques of metagenomics can be used. Turbomycin is one of the fi rst antibiotics to be discovered by metagenomics [198] . Isolation of long-chain acyltyrosine antibiotics from metagenomic libraries has also been reported [199] . Genes encoding enzymes responsible for the synthesis of secondary metabolites, are usually clustered on a contiguous piece of DNA. For expression of a single antibiotic there is a need for a large size DNA, which is a major challenge when DNA is isolated from soil, having high concentrations of humus and heavy metals as contaminants [200, 201] . But large insert metagenomic libraries can be prepared from marine samples with ease. By designing a suitable vector, which can accommodate large size inserts, it is possible to isolate novel bioactive compounds from marine unculturable actinomycetes [200, 201] . 
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